Background
==========

Serotonin syndrome is a condition characterized predominantly by neuromuscular symptoms and altered thermoregulation in response to serotonergic overtone. Treatment is focused on withdrawal of serotonergic agents, which leads to resolution in the majority of cases. However, if not recognized and treated, this syndrome can progress to a life-threatening state. Here, we describe a patient who overdosed on long-acting serotonergic agents in combination with several anti-serotonergic agents, including the 5-HTP~2A~ antagonist cyproheptadine, resulting in a delayed-onset serotonin syndrome.

Case Report
===========

A 24-year-old man with past medical history significant for depression and treatment-refractory schizoaffective disorder was brought in by ambulance after being found unresponsive. He was last seen normal approximately 7 h prior; at the scene, he was surrounded by multiple empty prescription bottles and intentional drug overdose was suspected. In the field, he was administered naloxone without a change in his status.

Upon arrival to the emergency department, the patient was afebrile (temperature 37.2°C) but was hypotensive (mean arterial pressure 59 mm Hg) and tachycardic (heart rate 116). Physical examination was notable for fixed pupils bilaterally and a Glasgow Coma Score (GCS) of 3. Laboratory studies were significant for a lactate 14.8 mmol/L, bicarbonate 16 mEq/L, a white blood cell count of 14.2×10^9^/L, creatinine 1.5 mg/dl, AST 121 U/L, ALT 55 U/L, and creatinine kinase 12 643 U/L.

QTc was prolonged at 549 ms, but QRS interval was normal. Urine toxicology screen was positive for amphetamines. All other laboratory parameters (including electrolytes, blood urea nitrogen, and blood gases) were normal at this time. The patient was subsequently intubated and admitted to the intensive care unit. Treatment initially consisted of supportive care, including vasopressor support for hemodynamic instability in the form of persistent hypotension, volume resuscitation for his acute kidney injury/rhabdomyolysis, and empiric antibiotic coverage with vancomycin and piperacillin-tazobactam for suspected aspiration pneumonia. He was also maintained on infusions of fentanyl, midazolam, and propofol for sedation.

On the second hospital day, the patient's hemodynamic instability resolved, leading to weaning of sedation and vasopressors. In addition, initial electrolyte abnormalities, elevated white count, and creatinine had normalized, with the exception of creatinine kinase and liver function tests, which were down-trending. However, physical examination was notable for fixed and pinpoint pupils, but with mildly improved neurological function. At this time, the patient's family provided the medications presumed to have caused his overdose, which included fluoxetine, bupropion, olanzapine, cyproheptadine, and risperidone ([Table 1](#t1-amjcaserep-19-604){ref-type="table"}).

On the third hospital day, the patient's temperature rose to 39.1°C and he was noted to have a marked change on examination, with spontaneous myoclonic jerks, rigors, asymmetric patellar reflexes, and nystagmus. This was accompanied by features of autonomic instability (systolic blood pressure of 189 mm Hg). Despite the delay in presentation, serotonin syndrome was suspected as the patient clearly had documented exposure to a serotonergic agent and per Hunter's Decision Rules for the diagnosis of serotonin toxicity, demonstrated spontaneous clonus (bilateral lower extremities), agitation, ocular clonus, fever, and hyperreflexia \[[@b1-amjcaserep-19-604]\]. It was thought that upon clearance of olanzapine and cyproheptadine (anti-serotonergic agents), serotonergic overtone from fluoxetine overdose was unmasked due to the longer half-life of this medication ([Table 1](#t1-amjcaserep-19-604){ref-type="table"}). To decrease additional serotonergic agent exposure, fentanyl was switched to hydromorphone and a lorazepam drip was initiated to manage his clonus and agitation. However, the patient's temperature continued to increase ([Figure 1](#f1-amjcaserep-19-604){ref-type="fig"}); therefore, a single dose of cyproheptadine 12 mg was administered. This resulted in a substantial decrease in temperature (39.9°C to 36.2°C), resolution of clonus and hyperreflexia, and improvement in GCS. Thus, cyproheptadine was continued at 2 mg every 2 h as needed, with an additional 12 mg over the next 72 h. By hospital day 5, no further signs of serotonin syndrome were exhibited and the patient demonstrated a normalization in vital signs (mean arterial pressure 86, heart rate 88) and laboratory parameters (creatinine 0.64 mg/dL, alkaline phosphatase 145 U/L, alanine aminotransferase 79 U/L, creatine kinase 728 U/L, lactate 1.0 mmol/L, bicarbonate 25 mEq/L) He was subsequently extubated and was discharged to inpatient psychiatry on hospital day 8 for further psychiatric management.

Discussion
==========

This patient presented with a unique manifestation of delayed serotonin syndrome due to co-ingestion of shorter-half-life serotonin antagonists (olanzapine, cyproheptadine) with longer-acting serotonergic agents (fluoxetine). The patient's poly-pharmacy for depression (fluoxetine), schizoaffective disorder (olanzapine, risperidone), and insomnia (cyproheptadine) contributed to the complexity of this case.

Cyproheptadine and olanzapine are reported to have 16-h \[[@b2-amjcaserep-19-604]\] and 30-h half-lives, respectively. \[[@b3-amjcaserep-19-604]\] Doses as low as 18 mg of cyproheptadine provide near-complete antagonism of serotonin receptors \[[@b2-amjcaserep-19-604]\]. At 80 h post-ingestion, over 95% of cyproheptadine should be eliminated from a given patient. This time course corresponds to the delayed-onset of our patient's symptoms, thus leading to the high suspicion of delayed serotonin syndrome. In addition, the patient had a marked improvement in his fever curve, muscle clonus, rigidity, and mental status when cyproheptadine was re-administered with lorazepam. At this time, his laboratory abnormalities had grossly normalized, minimizing the likelihood of alternative etiologies. The prompt response to re-administration of cyproheptadine is consistent with prior reports of this agent's use in serotonin syndrome \[[@b4-amjcaserep-19-604]\]. Although olanzapine has not been utilized for the treatment of serotonin syndrome, withdrawal of this agent has been implicated in revealing serotonin syndrome in a patient receiving concurrent serotonergic agents \[[@b5-amjcaserep-19-604]\]. Risperidone may have also conferred a protective effect \[[@b6-amjcaserep-19-604]\], although serotonin syndrome has been reported with this agent in cases of co-administration with SSRIs \[[@b7-amjcaserep-19-604]\].

In selective serotonin reuptake inhibitor (SSRI) overdose, the reported onset of serotonin syndrome is normally within 13 h, with the majority of overdoses leading to symptom onset within 4 h \[[@b8-amjcaserep-19-604]\]. Isolated case reports of delayed-onset serotonin syndrome have been described, although not exceeding 24 h \[[@b9-amjcaserep-19-604]\]. Our patient overdosed on fluoxetine (time to peak concentration -- Tmax 6 h), but the drug's active metabolite, norfluoxetine, possesses a markedly prolonged Tmax of 48 h \[[@b10-amjcaserep-19-604]\]. The delay to serotonergic symptoms in this patient (80 h) is the longest reported delay in an intentional SSRI overdose, likely secondary to the co-ingestions described above. Notably, other toxidromes were considered given his mixed ingestion, including anti-cholinergic toxicity and neuroleptic malignant syndrome. The patient did not receive any medications that could have induced malignant hyperthermia. Neuroleptic malignant syndrome is typically hyporeflexic in nature with rigid rigidity in all muscle groups; this patient had hyper-reflexia localized to the lower extremities. Although this patient had agitated delirium consistent with anticholinergic toxidromes, the initial presentation of miosis, with altered muscle tone made this syndrome less likely. The profound response to cyproheptadine this patient exhibited would not be expected with either of these toxidromes but has been documented in serotonin syndrome. Alcohol withdrawal was a possible cofounder in this patient given the delayed hyperadrenergic state that this syndrome generates; however, if it was the sole toxidrome present, the continuous lorazepam infusion should have adequately treated his symptoms without the marked response to cyproheptadine administration. Other conditions such as meningoencephalitis and metabolic encephalopathy were felt to be less likely given the timing of the case with an intentional overdose and profound response to cyproheptadine. Potential infectious and metabolic etiologies were considered less likely given how rapidly the patient's laboratory parameters normalized, while the patient remained symptomatic. A major limitation of this case report was the inability to obtain serum or urine levels of the ingested agents. This would have allowed a clear depiction of the toxicokinetics of these drugs in this patient and would have allowed trending of serum levels to symptom manifestations.

Conclusions
===========

Combined ingestion of cyproheptadine and olanzapine in a multi-drug overdose resulted in an early "protective" effect, leading to delayed serotonin syndrome in the setting of concurrent fluoxetine and trazodone overdose. Evidence from this report demonstrates that the onset of serotonin syndrome can be delayed and that a high index of suspicion is required for diagnosis, especially in patients with co-ingestion of serotonin antagonists. Serum level monitoring may be useful if multiple agents such as these are co-ingested. Lastly, further study is needed to investigate the potential role of olanzapine and other serotonin antagonists in the early treatment of this condition.
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###### 

Suspected ingested medications (including elimination half-lives) with quantities available to patient based on prescription fill data.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Drug and dose**                               **Quantity available**   **Half-life \[[@b1-amjcaserep-19-604],[@b4-amjcaserep-19-604]\]**   **Receptors involved \[[@b1-amjcaserep-19-604],[@b3-amjcaserep-19-604],[@b4-amjcaserep-19-604]\]**
  ----------------------------------------------- ------------------------ ------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  **Serotonin antagonists**                                                                                                                    

  Olanzapine (5 mg and 10 mg)                     60                       33 hours                                                            5HT~2A~, 5HT~2C~, dopamine and HT3 antagonist

  Risperidone (3 mg)                              120                      3 to 20 hours                                                       5HT~2A~, 5HT~7~, D~2~ antagonist

  Cyproheptadine (4 mg)                           60                       16 hours                                                            5HT~2~ Antagonist

  **Serotonergic agents/serotonergic agonists**                                                                                                

  Fluoxetine (20 mg)                              30                       Fluoxetine: 4 to 6 days\                                            5HT reuptake inhibition
                                                                           Norfluoxetine: 7 to 15 days                                         

  Trazodone (50 mg)                               30                       6 h                                                                 5HT~2A~, 5HT~2C~ agonist

  **Other Adrenergic Agents Ingested**                                                                                                         

  Bupropion SR (100 mg) and XL (150 mg)           60                       14 to 21 h                                                          Norepinephrine, dopamine reuptake inhibition
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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